Cited 0 times in
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.date.accessioned | 2023-07-12T02:28:12Z | - |
dc.date.available | 2023-07-12T02:28:12Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195319 | - |
dc.description.abstract | Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | CLINICAL AND MOLECULAR HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Biomarkers, Tumor | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / diagnosis | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / pathology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Neoplasms* / diagnosis | - |
dc.subject.MESH | Liver Neoplasms* / pathology | - |
dc.subject.MESH | Prothrombin / metabolism | - |
dc.subject.MESH | Vitamin K | - |
dc.subject.MESH | Vitamins | - |
dc.subject.MESH | alpha-Fetoproteins | - |
dc.title | Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Bao Nguyen Toan | - |
dc.contributor.googleauthor | Chee-Kiat Tan | - |
dc.contributor.googleauthor | Irsan Hasan | - |
dc.contributor.googleauthor | Lyana Setiawan | - |
dc.contributor.googleauthor | Ming-Lung Yu | - |
dc.contributor.googleauthor | Namiki Izumi | - |
dc.contributor.googleauthor | Nguyen Nguyen Huyen | - |
dc.contributor.googleauthor | Pierce Kah-Hoe Chow | - |
dc.contributor.googleauthor | Rosmawati Mohamed | - |
dc.contributor.googleauthor | Stephen Lam Chan | - |
dc.contributor.googleauthor | Tawesak Tanwandee | - |
dc.contributor.googleauthor | Teng-Yu Lee | - |
dc.contributor.googleauthor | Thi Thanh Nguyen Hai | - |
dc.contributor.googleauthor | Tian Yang | - |
dc.contributor.googleauthor | Woo-Chang Lee | - |
dc.contributor.googleauthor | Henry Lik Yuen Chan | - |
dc.identifier.doi | 10.3350/cmh.2022.0212 | - |
dc.contributor.localId | A00385 | - |
dc.relation.journalcode | J00557 | - |
dc.identifier.eissn | 2287-285X | - |
dc.identifier.pmid | 36710606 | - |
dc.subject.keyword | Alpha-fetoprotein | - |
dc.subject.keyword | Biomarkers | - |
dc.subject.keyword | Carcinoma, hepatocellular | - |
dc.subject.keyword | Consensus | - |
dc.subject.keyword | PIVKA-II | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.citation.volume | 29 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 277 | - |
dc.citation.endPage | 292 | - |
dc.identifier.bibliographicCitation | CLINICAL AND MOLECULAR HEPATOLOGY, Vol.29(2) : 277-292, 2023-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.